Further investigation has demonstrated that this cascade of events is initiated by CD8+ T cell-dependent stimulation of the NLRP3 inflammasome in tumor cells which drives the release of HSP70 and serves to dampen the efficacy of anti- PD-1 antibody immunotherapy. Here, RPL17 is linked to neoplasm.